• Sun. Nov 15th, 2026

Johns Hopkins Researchers Identify Early Brain Markers That Could Detect Alzheimer’s a Decade Before Memory Loss

Alzheimer’s disease may begin leaving detectable structural clues in the human brain as much as a decade before any clinical memory problems or cognitive symptoms become apparent. In a significant step forward for neurodegenerative research, scientists at Johns Hopkins University have identified two specific brain regions that show definitive signs of tissue deterioration considerably earlier than the hippocampus, the area traditionally examined by medical professionals for evidence of the debilitating disease.

The discovery, which sheds new light on the protracted, silent progression of the condition, could eventually help physicians and clinical specialists recognize Alzheimer’s years—or even decades—before outward symptoms develop. Researchers hope that pinpointing these early indicators will create a crucial window of opportunity, potentially allowing preventative treatments to begin during a phase when interventions have the greatest possible chance of protecting healthy brain tissue and preserving cognitive function.

By examining hundreds of advanced brain scans, the research team discovered that the entorhinal cortex and the amygdala—two interconnected regions deeply involved in processing memory and emotion—begin losing gray matter volume significantly earlier than the hippocampus. These anatomical changes offer vital new insights into the earliest phases of Alzheimer’s pathology and outline a promising path forward for detecting the disease before significant and irreversible cognitive decline takes hold.

"We have found that there are early changes in the brain manifesting the clinical biomarkers of atrophy as much as a decade before there are clinical symptoms," said Michael Miller, a biomedical engineer and senior author of the study. "It’s at least a 5-to-10-year play where your brain is changing. Imagine if we could start to treat the neurodegenerative changes at the 2, 3 or 4-year point rather than after 15 years when the changes are manifesting in memory symptoms. That’s the great promise here for your loved ones who are at risk."

The findings were recently published in the scientific journal NeuroImage Reports and are being showcased at Neuroscience 2026, the annual meeting of the Society for Neuroscience. While the research marks an important milestone in understanding the temporal progression of Alzheimer’s, experts emphasize that further investigation is required before these findings can be translated into routine clinical diagnostic tools.

Detecting Alzheimer’s Before Memory Loss Begins

As the most common cause of dementia worldwide affecting tens of millions of individuals, Alzheimer’s disease is rarely recognized for what it truly is at its inception. The disease does not begin on the day a patient or their family member first notices episodes of forgetfulness, mild confusion, or disorientation. Instead, the underlying cellular changes associated with Alzheimer’s can quietly accumulate and compound within the central nervous system for decades before any noticeable clinical symptoms emerge on the surface.

Scientists have long believed that this extended period of silent disease progression may provide a vital therapeutic opportunity. Interventions and medical therapies that begin before widespread cellular damage occurs could theoretically do far more to safeguard a patient’s memory, reasoning abilities, and overall independence. However, successfully taking advantage of that preclinical window requires reliable, highly sensitive methods to identify the presence of the disease in its earliest stages, long before an individual walks into a neurologist’s office complaining of cognitive issues.

One of the most promising approaches in modern neurology involves the use of biomarkers—measurable biological indicators that can signal the presence, severity, or progression of a specific disease process. In the context of Alzheimer’s research, these biological markers could eventually help clinicians reveal who is quietly developing the condition years before symptoms become apparent to loved ones or coworkers.

"Our goal is to be able to treat individuals before the symptoms of Alzheimer’s disease develop so that they may be delayed or even stopped," said Marilyn Albert, a co-author of the study and the director of the Johns Hopkins Alzheimer’s Disease Research Center.

Two Brain Regions Reveal Earlier Warning Signs

To investigate precisely where the earliest detectable changes take place within the human brain, the research team conducted a comprehensive analysis of hundreds of magnetic resonance imaging (MRI) scans and positron emission tomography (PET) scans. These datasets were collected through two independent, well-established research initiatives: the Alzheimer’s Disease Neuroimaging Initiative and the Biomarkers of Cognitive Decline Among Normal Individuals study.

The comprehensive scans tracked human subjects at various stages of health and disease progression over extended periods. This diverse cohort included cognitively normal individuals, people experiencing mild cognitive impairment, and patients who ultimately succumbed to the disease, allowing researchers to build a longitudinal picture of how the brain changes over time.

Across the examined groups, the researchers observed a striking and consistent anatomical pattern. The entorhinal cortex and the amygdala, both of which are situated in close anatomical proximity to the hippocampus, demonstrated greater relative tissue loss and structural shrinkage during the earliest stages of Alzheimer’s pathology than the hippocampus itself.

This distinction is clinically significant because the hippocampus has historically served as the primary focal point when physicians and radiologists search for structural evidence of Alzheimer’s-related damage. The hippocampus plays a foundational role in the consolidation of new memories, making it a natural area of interest, but its relative stability during the earliest preclinical phases has historically limited how early doctors can spot trouble.

Meanwhile, the two newly highlighted regions perform distinct and equally critical cognitive and emotional functions. The entorhinal cortex acts as a major hub for memory processing, helping the brain retrieve previously stored information, while the amygdala contributes heavily to emotional memory, shaping how emotional experiences are processed, encoded, and remembered. Their earlier vulnerability and shrinkage suggest that examining these structures in tandem could reveal subtle signs of Alzheimer’s disease that might otherwise be missed if attention remains focused exclusively on the hippocampus.

Brain Shrinkage Linked to Alzheimer’s Tau Protein

Beyond documenting the physical timing of tissue loss, the researchers also uncovered a critical biological connection between the observed shrinkage of gray matter and tau, a protein intimately linked to the pathology of Alzheimer’s disease.

Under normal, healthy physiological conditions, tau proteins play a supportive role by helping to stabilize and maintain the internal structural skeleton of nerve cells, known as microtubules. In the brains of individuals with Alzheimer’s disease, however, the tau proteins undergo chemical alterations that cause them to detach from microtubules and clump together abnormally. These rogue proteins form tangled bundles that disrupt healthy cellular transport and severely interfere with normal brain function.

By utilizing advanced PET imaging techniques alongside digital pathology methods, the scientists discovered that the specific areas of gray matter shrinkage observed in the brain scans overlapped closely with regions showing high concentrations of tau-related changes. Gray matter is composed of massive numbers of nerve cell bodies, synapses, and dendrites, making it utterly essential for processing information, regulating thoughts, and controlling bodily functions throughout the central nervous system.

This spatial and biological relationship significantly strengthens the hypothesis that measuring tissue loss in the entorhinal cortex and the amygdala could serve as a highly effective, practical indicator of early-stage Alzheimer’s disease. The research team believes that quantifying structural changes in both regions, rather than relying solely on modifications within the hippocampus, could eventually improve the predictive accuracy of diagnostic screenings for individuals at risk of cognitive decline.

As modern neuroimaging technologies continue to evolve, becoming increasingly accessible and less economically burdensome, this expanded diagnostic approach could eventually transition from experimental research into standard clinical practice. For individuals with a documented family history of Alzheimer’s disease or other established genetic and lifestyle risk factors, researchers envision a future where medical professionals might routinely examine these specific brain regions as early as a person’s thirties or forties.

"As biomarkers and treatments become increasingly available, knowing who is going to have cognitive decline is going to be really important," said co-author Meaghan Morris, a neuropathologist who specializes in the study of Alzheimer’s disease and related dementias. "This could really play into better risk stratification for identifying who is going to have cognitive decline in the near future — and treating people earlier and earlier to hopefully slow the course of the disease."

A Potential New Path Toward Earlier Alzheimer’s Treatment

While the findings from Johns Hopkins University offer a compelling new direction for the field of neurology, the research team is quick to note that substantial work remains ahead. More investigation is necessary before medical practitioners can reliably utilize these specific structural brain changes as an everyday diagnostic tool. The current study successfully identifies potential early biomarkers of atrophy, but it does not yet establish a finalized clinical test capable of definitively predicting Alzheimer’s disease years in advance for individual patients.

The logical next step for the research group is to investigate what happens within these vulnerable brain regions at a much finer, microscopic scale. The scientists aim to gain a deeper understanding of the complex molecular changes that surround the abnormal accumulation of tau protein and to map out the precise biological mechanisms that connect those protein tangles to the progressive loss of healthy brain tissue.

By uncovering the detailed molecular processes driving this early degeneration, researchers hope to identify entirely new therapeutic targets. These future treatments could theoretically be designed to interrupt the Alzheimer’s disease process long before extensive, irreversible damage can occur within the brain.

"Our future work is to better show the molecular neighborhoods associated with these Tau protein changes as localized by these clinical biomarkers of atrophy," Miller concluded. "Once we know more about the molecular neighborhoods, we can develop therapies."